Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories announced a definitive agreement to acquire Exact Sciences through a cash merger. Each outstanding Exact Sciences common share will be converted at closing into the right to receive $105.00 in cash, subject to customary terms and tax withholding, with Exact Sciences becoming a wholly owned Abbott subsidiary.
The deal is conditioned on approval by holders of at least a majority of Exact Sciences shares, required regulatory clearances including expiration or termination of the Hart-Scott-Rodino waiting period, absence of legal restraints, and satisfaction of representations, covenants, and a no–material adverse effect condition on Exact Sciences. In connection with signing, Abbott obtained a commitment for up to $20,000,000,000 of senior unsecured bridge loans to support the transaction.
Abbott Laboratories filed its Q3 2025 report with steady profit and higher sales. Net sales were $11,369 million, up from $10,635 million a year ago, while diluted EPS held at $0.94. Year‑to‑date, sales reached $32,869 million and diluted EPS rose to $2.70 from $2.38. Operating earnings improved to $2,057 million, supported by Medical Devices growth (notably Diabetes Care and Electrophysiology) and stronger Established Pharmaceuticals, partly offset by lower COVID‑19 testing revenue.
Cash from operations was $6,251 million for the first nine months, funding $1,503 million of long‑term debt repayments and $3,086 million in dividends, with purchases of common shares of $591 million. The company recorded 2025 restructuring charges of $197 million and $25 million of asset impairments to streamline diagnostics and devices. Remaining performance obligations were $6.0 billion in Diagnostics and $436 million in Medical Devices. As of September 30, 2025, common shares outstanding were 1,738,871,947.
Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.
The company highlighted the use of non-GAAP financial measures to evaluate ongoing business performance. These measures adjust for items that can be unusual or unpredictable, including acquisition-related expenses, restructuring actions, fair value changes in contingent consideration, certain regulatory costs, adjustments tied to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit from resolution of prior-year tax positions, and excess tax benefits from share-based compensation. They also exclude intangible amortization expense to show results excluding these costs. Management believes these metrics provide useful insight for investors, while cautioning they should be considered alongside GAAP results.
John G. Stratton, a director of Abbott Laboratories (ABT), had 293 stock-equivalent units credited on 09/30/2025 under a grantor trust that converts director fees into units that track Abbott share returns. The units are valued at $133.94 each in this filing and the reporting person’s total beneficial ownership after the transaction is reported as 12,663 shares or share equivalents. The filing explains these units are paid in cash generally at age 65 or upon retirement from the board and that the balance includes units from a dividend reinvestment feature. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Patricia Paola Gonzalez, a director of Abbott Laboratories (ABT), had a non-derivative transaction on 09/30/2025 that credited 246 stock equivalent units at an indicated per-share reference of $133.94. After the reported transaction, the filing shows she beneficially owned 4,922 shares/stock-equivalent units. The filing explains these credits represent director fees placed into a stock equivalent unit account under a director grantor trust, which are paid in cash generally at age 65 or upon retirement from the board and earn the same return as if invested in Abbott shares. The reported Form 4 was signed via attorney-in-fact on 10/02/2025.
Robert J. Alpern, a director of Abbott Laboratories (ABT), reported a transaction dated 09/30/2025 on a Form 4. The filing shows an acquisition of 58 common share equivalents recorded at $133.94 per share and a post-transaction beneficial balance of 10,300 stock-equivalent units. The filing notes these units represent director fees credited to a grantor trust that mirror Abbott share returns and are generally paid in cash at age 65 or upon board retirement; the balance also includes units from a dividend reinvestment feature. The Form 4 was signed on behalf of Mr. Alpern by an attorney-in-fact on 10/02/2025.
Abbott Laboratories reporting person John A. McCoy Jr., Vice President and Controller, is disclosed as selling 79 common shares on 09/01/2025 at a price of $132.66 per share. After the reported disposition, Mr. McCoy beneficially owns 20,982 common shares directly. The filing also notes an indirect interest in Abbott shares held in a profit sharing/stock retirement trust, with the balance in that trust stated as of September 1, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. McCoy on 09/03/2025.
Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares. He also reports indirect beneficial ownership of 363 shares held in a Profit Sharing Trust. The filing is signed by an attorney-in-fact on behalf of Mr. Boudreau.
Philip P. Boudreau, EVP and CFO of Abbott Laboratories (ABT), filed a Form 4 reporting insider sales dated 08/08/2025. The filing lists a sale transaction reported at a weighted average price of $134.551 and notes transaction prices in the range $134.551 to $134.58. The table shows 5,550 shares sold (denoted D) and a direct beneficial ownership following the reported transaction of 51,003 shares. It also reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.
The Form 4 is signed on behalf of Mr. Boudreau by an attorney-in-fact and dated 08/11/2025. The filing includes an explicit offer to provide detailed per-price sale breakdowns upon request and discloses the reporting person’s title and relationship to the issuer. No additional financial metrics, forward-looking statements, or explanations of purpose for the sale are provided in the filing.
Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.
The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.